|
1
|
Griguolo G, Brasó-Maristany F, González-Farré B, Pascual T, Chic N, Saurí T, Kates R, Gluz O, Martínez D, Paré L, Tsvetkova V, Pesantez D, Vidal M, Adamo B, Muñoz M, Galván P, Barberá L, Cuatrecasas M, Christgen M, Kreipe H, Monge-Escartín I, Villagrasa P, Soy D, Giarratano T, Dieci MV, Conte P, Harbeck N, Guarneri V, Prat A. ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. Cancers (Basel) 2020; 12:E1902. [PMID: 32674482 PMCID: PMC7409149 DOI: 10.3390/cancers12071902] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2020] [Revised: 07/06/2020] [Accepted: 07/08/2020] [Indexed: 11/20/2022] Open
Abstract
Trastuzumab emtansine (T-DM1) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive (HER2+) metastatic breast cancer (BC) and for residual disease after neoadjuvant therapy; however, not all patients benefit. Here, we hypothesized that the heterogeneity in the response seen in patients is partly explained by the levels of human epidermal growth factor receptor 2 gene (ERBB2) mRNA. We analyzed ERBB2 expression using a clinically applicable assay in formalin-fixed paraffin-embedded (FFPE) tumors (primary or metastatic) from a retrospective series of 77 patients with advanced HER2+ BC treated with T-DM1. The association of ERBB2 levels and response was further validated in 161 baseline tumors from the West German Study (WGS) Group ADAPT phase II trial exploring neoadjuvant T-DM1 and 9 in vitro BC cell lines. Finally, ERBB2 expression was explored in 392 BCs from an in-house dataset, 368 primary BCs from The Cancer Genome Atlas (TCGA) dataset and 10,071 tumors representing 33 cancer types from the PanCancer TCGA dataset. High ERBB2 mRNA was found associated with better response and progression-free survival in the metastatic setting and higher rates of pathological complete response in the neoadjuvant setting. ERBB2 expression also correlated with in vitro response to T-DM1. Finally, our assay identified 0.20-8.41% of tumors across 15 cancer types as ERBB2-high, including gastric and esophagus adenocarcinomas, urothelial carcinoma, cervical squamous carcinoma and pancreatic cancer. In particular, we identified high ERBB2 mRNA in a patient with HER2+ advanced gastric cancer who achieved a long-lasting partial response to T-DM1. Our study demonstrates that the heterogeneity in response to T-DM1 is partly explained by ERBB2 levels and provides a clinically applicable assay to be tested in future clinical trials of breast cancer and other cancer types.
Collapse
Affiliation(s)
- Gaia Griguolo
- Division of Medical Oncology 2, Istituto Oncologico Veneto IOV—IRCCS, 35128 Padova, Italy; (G.G.); (T.G.); (M.V.D.); (P.C.); (V.G.)
- Department of Surgery, Oncology and Gastroenterology, University of Padova, 35124 Padova, Italy;
| | - Fara Brasó-Maristany
- Department of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (F.B.-M.); (T.P.); (N.C.); (T.S.); (D.M.); (D.P.); (M.V.); (B.A.); (M.M.); (P.G.); (L.B.)
- Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain;
| | - Blanca González-Farré
- Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain;
- Department of Pathology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain;
| | - Tomás Pascual
- Department of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (F.B.-M.); (T.P.); (N.C.); (T.S.); (D.M.); (D.P.); (M.V.); (B.A.); (M.M.); (P.G.); (L.B.)
- Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain;
- SOLTI breast cancer cooperative group, 08008 Barcelona, Spain; (L.P.); (P.V.)
| | - Núria Chic
- Department of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (F.B.-M.); (T.P.); (N.C.); (T.S.); (D.M.); (D.P.); (M.V.); (B.A.); (M.M.); (P.G.); (L.B.)
- Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain;
| | - Tamara Saurí
- Department of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (F.B.-M.); (T.P.); (N.C.); (T.S.); (D.M.); (D.P.); (M.V.); (B.A.); (M.M.); (P.G.); (L.B.)
- Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain;
| | - Ronald Kates
- The West German Study Group, 41061 Mönchengladbach, Germany; (R.K.); (O.G.)
| | - Oleg Gluz
- The West German Study Group, 41061 Mönchengladbach, Germany; (R.K.); (O.G.)
- Ev. Hospital Bethesda, Breast Center Niederrhein, 41061 Mönchengladbach, Germany
- University Clinics Cologne, 50937 Cologne, Germany
| | - Débora Martínez
- Department of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (F.B.-M.); (T.P.); (N.C.); (T.S.); (D.M.); (D.P.); (M.V.); (B.A.); (M.M.); (P.G.); (L.B.)
- Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain;
| | - Laia Paré
- SOLTI breast cancer cooperative group, 08008 Barcelona, Spain; (L.P.); (P.V.)
| | - Vassilena Tsvetkova
- Department of Surgery, Oncology and Gastroenterology, University of Padova, 35124 Padova, Italy;
| | - David Pesantez
- Department of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (F.B.-M.); (T.P.); (N.C.); (T.S.); (D.M.); (D.P.); (M.V.); (B.A.); (M.M.); (P.G.); (L.B.)
- Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain;
| | - Maria Vidal
- Department of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (F.B.-M.); (T.P.); (N.C.); (T.S.); (D.M.); (D.P.); (M.V.); (B.A.); (M.M.); (P.G.); (L.B.)
- Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain;
- SOLTI breast cancer cooperative group, 08008 Barcelona, Spain; (L.P.); (P.V.)
| | - Barbara Adamo
- Department of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (F.B.-M.); (T.P.); (N.C.); (T.S.); (D.M.); (D.P.); (M.V.); (B.A.); (M.M.); (P.G.); (L.B.)
- Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain;
| | - Montserrat Muñoz
- Department of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (F.B.-M.); (T.P.); (N.C.); (T.S.); (D.M.); (D.P.); (M.V.); (B.A.); (M.M.); (P.G.); (L.B.)
- Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain;
- SOLTI breast cancer cooperative group, 08008 Barcelona, Spain; (L.P.); (P.V.)
| | - Patricia Galván
- Department of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (F.B.-M.); (T.P.); (N.C.); (T.S.); (D.M.); (D.P.); (M.V.); (B.A.); (M.M.); (P.G.); (L.B.)
- Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain;
| | - Laura Barberá
- Department of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (F.B.-M.); (T.P.); (N.C.); (T.S.); (D.M.); (D.P.); (M.V.); (B.A.); (M.M.); (P.G.); (L.B.)
- Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain;
| | - Miriam Cuatrecasas
- Department of Pathology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain;
| | - Mathias Christgen
- Medical School Hannover, Institute of Pathology, 30625 Hannover, Germany; (M.C.); (H.K.)
| | - Hans Kreipe
- Medical School Hannover, Institute of Pathology, 30625 Hannover, Germany; (M.C.); (H.K.)
| | - Inés Monge-Escartín
- Pharmacy Department, Division of Medicines, Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (I.M.-E.); (D.S.)
| | - Patricia Villagrasa
- SOLTI breast cancer cooperative group, 08008 Barcelona, Spain; (L.P.); (P.V.)
| | - Dolors Soy
- Pharmacy Department, Division of Medicines, Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (I.M.-E.); (D.S.)
| | - Tommaso Giarratano
- Division of Medical Oncology 2, Istituto Oncologico Veneto IOV—IRCCS, 35128 Padova, Italy; (G.G.); (T.G.); (M.V.D.); (P.C.); (V.G.)
| | - Maria Vittoria Dieci
- Division of Medical Oncology 2, Istituto Oncologico Veneto IOV—IRCCS, 35128 Padova, Italy; (G.G.); (T.G.); (M.V.D.); (P.C.); (V.G.)
- Department of Surgery, Oncology and Gastroenterology, University of Padova, 35124 Padova, Italy;
| | - Pierfranco Conte
- Division of Medical Oncology 2, Istituto Oncologico Veneto IOV—IRCCS, 35128 Padova, Italy; (G.G.); (T.G.); (M.V.D.); (P.C.); (V.G.)
- Department of Surgery, Oncology and Gastroenterology, University of Padova, 35124 Padova, Italy;
| | - Nadia Harbeck
- Breast Center, Department of Gynecology and Obstetrics, University of Munich (LMU) and CCCLMU, 80337 Munich, Germany;
| | - Valentina Guarneri
- Division of Medical Oncology 2, Istituto Oncologico Veneto IOV—IRCCS, 35128 Padova, Italy; (G.G.); (T.G.); (M.V.D.); (P.C.); (V.G.)
- Department of Surgery, Oncology and Gastroenterology, University of Padova, 35124 Padova, Italy;
| | - Aleix Prat
- Department of Medical Oncology, Hospital Clínic de Barcelona, 08036 Barcelona, Spain; (F.B.-M.); (T.P.); (N.C.); (T.S.); (D.M.); (D.P.); (M.V.); (B.A.); (M.M.); (P.G.); (L.B.)
- Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain;
- SOLTI breast cancer cooperative group, 08008 Barcelona, Spain; (L.P.); (P.V.)
| |
Collapse
|